In our previous work, an immune subtype classification for ER+/PR-/HER2- BC with RNA-seq data was established to distinguish between immune-hot and -cold tumors to provide guidance for immune checkpoint inhibitor (ICI) therapy. However, considering the economic costs, the clinical application of...
If yourbreast cancerhas a significant number of receptors for either estrogen or progesterone, it’s considered hormone-receptor positive. Tumors that are ER/PR-positive are much more likely to respond to hormone therapy than tumors that are ER/PR-negative. ...
HER2-expressing breast cancers (ie, ER negative, PR negative, and HER2 positive) exhibit overexpression of genes in the HER2-signaling pathway (6). ... AI Phipps - 《J Natl Cancer Inst》 被引量: 29发表: 2011年 Prognostic and Predictive Biomarkers in Breast Cancer: Past, Present and Future...
The level of ER expression by immunohistochemistry (% of positive tumor cells) was not different between ER+HER2- and ER+HER2low cases (P = 0.54; t-test). Figure 1 HER2 IHC expression (HER2- versus HER2low) versus HER2 copy number determined by ISH (A) and versus mRNA ERBB2 ...
4). Of note, even though the Luminal A and the Basal-like signatures were associated with CelTIL response, estrogen receptor (ER) and progesterone receptor (PR) protein expression were not (Supplementary Fig. 5). ERBB2/HER2 expression and HER3-DXd response Our pre-treatment RNA-based ...
4). Of note, even though the Luminal A and the Basal-like signatures were associated with CelTIL response, estrogen receptor (ER) and progesterone receptor (PR) protein expression were not (Supplementary Fig. 5). ERBB2/HER2 expression and HER3-DXd response Our pre-treatment RNA-based ...
1A), in both ER+ and ER- tumors. In the ER+ cohort, there was no significant association between any of the clinicopathologic features between HER2- and HER2low breast cancer, except for the HER2 copy numbers. The level of ER expression by immunohistochemistry (% of positive tumor ...
The immunohistochemical (IHC) surrogates for four of the five subtypes have been developed by detection of ER, PR, HER2, HER1, and CK5/6 in breast cancers. To date, the Ihc surrogate for the normal-like subtype is still ambiguous. However, some investigators treat the so-called "...
In the present study, epithelial cells extracted fresh from breast cancer patient tumors classified as HER2 negative (HER2-, n = 34 of which 33 were estrogen receptor positive) and healthy subjects (n = 16) were evaluated along with reference breast cancer cell lines (n = 19). Live cell ...
Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer is the most prevalent type of breast cancer, in which endocrine therapy resistance and distant relapse remain unmet challenges. Accurate molecular classification is urgently required for guiding pre...